DYAIHIGH SIGNALFINANCIAL10-K

DYAI faces deteriorating financial conditions with stockholders' equity cut in half, substantially higher current liabilities, and worsening operating cash flow alongside declining revenue.

The company's financial position has meaningfully weakened with stockholders' equity dropping from $2.5M to just $1.2M while current liabilities increased substantially to $3.7M, creating potential liquidity pressures. The addition of new risk language around Nasdaq delisting requirements and going concern warnings, combined with worsening operational performance, signals mounting financial distress for this small biotechnology company.

Comparing 2026-03-25 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

DYAI's financial metrics deteriorated across multiple dimensions during the period, with revenue declining 11.6% to $3.1M while operating losses expanded meaningfully to -$7.2M and net losses widened to -$7.4M. The balance sheet shows concerning trends with stockholders' equity halving to $1.2M, current liabilities rising substantially to $3.7M, and cash reserves declining to $4.6M from $6.5M. Operating cash flow worsened notably to -$5.7M, painting a picture of mounting financial pressure and deteriorating liquidity for this small biotech operation.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+50.6%
$2.4M→$3.7M

Current liabilities surged 50.6% — significant near-term obligations; verify ability to meet short-term debt.

Stockholders Equity
Balance Sheet
-50.1%
$2.5M→$1.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
-43.5%
-$4.0M→-$5.7M

Operating cash flow fell 43.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
-29%
$6.5M→$4.6M

Cash decreased 29% — monitor burn rate and upcoming capital needs.

Net Income
P&L
-26.8%
-$5.8M→-$7.4M

Net income declined 26.8% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-21.9%
-$5.9M→-$7.2M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Total Liabilities
Balance Sheet
+16.8%
$7.5M→$8.7M

Liabilities increased 16.8% — monitor debt-to-equity ratio and interest coverage.

Revenue
P&L
-11.6%
$3.5M→$3.1M

Revenue softened 11.6% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-26
ADDED
As of March 24, 2026, the registrant had 36,438,703 sh ares of common stock outstanding.
We heavily rely on contracts with third-party contract research organizations ( CROs ) and other third-party service providers across all aspects of our business, including to conduct our research and development, pre-clinical, CMC ( Chemistry, Manufacturing, and Controls ) and cGMP ( current Good Manufacturing Practices ) manufacturing, fill and finish, and potential clinical trials, which may not be available to the Company on commercially reasonable terms or at all.
Our employees and independent contractors, including principal investigators, CROs, CDMOs, consultants, vendors, and other service providers, may engage in misconduct or other improper activities, including noncompliance with applicable laws, regulations, and our internal policies and procedures.
Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results.
If we fail to comply with the listing standards of the Nasdaq Stock Market, our common stock may be delisted, adversely affecting the liquidity and market price of our common stock, as well as our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern.
( Dyadic , we , us , our , or the Company ), doing business as Dyadic Applied BioSolutions, is a global biotechnology company based in Jupiter, Florida, with operations in the United States and a satellite office in the Netherlands.
The Company develops, manufactures, and commercializes precision-engineered, animal-free recombinant proteins and enzymes for applications in life sciences, food and nutrition, and bio-industrial markets.
These products are produced using Dyadic s proprietary microbial expression platforms, including the C1 and Dapibus systems, which enable scalable and cost-effective production of recombinant proteins used in research, diagnostics, cell culture, nutrition, and industrial biotechnology.
The Company utilizes third-party consultants, contract research organizations, and manufacturing partners to support certain research, development, and commercial activities.
Dyadic s commercialization strategy includes direct product sales, distribution partnerships, manufacturing collaborations, and technology licensing agreements, which may include annual licensing fees, milestone payments, development funding, product supply revenues, and revenue-sharing arrangements.
REMOVED
Emalfarb, our President and Chief Executive Officer, is the Trustee of the Francisco Trust.
Thomas Emalfarb may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Francisco Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
The amount of accrued interest as of December 31, 2024, is $20,000.
Represents the following options exercised: (a) 25,000 stock options exercised at $0.97, and (b) 30,000 stock options exercised at $1.36.
Represents the vesting of 212,709 RSUs granted to executives and key personnel, 174,837 RSUs granted to the Board of Directors, and 50,000 RSUs granted to a consultant.
Represents the cancellation of RSUs granted to a former member of the Board of Directors.
Emalfarb, our President and Chief Executive Officer, is the Trustee of the Irrevocable Trust and the brother of Mr.
Emalfarb, who is the sole beneficiary of the Irrevocable Trust.
Emalfarb, as sole beneficiary of the Irrevocable Trust, therefore, may be deemed to have voting, dispositive and investment power with respect to the shares of common stock held by the Irrevocable Trust and disclaims any such beneficial ownership other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
For the year ended December 31, 2024, $500,000 of the Convertible Notes held by Mr.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →